
    
      This single ascending dose study will evaluate the safety, tolerability, and PK of single
      doses of galidesivir vs. placebo administered as IV infusions in healthy subjects enrolled in
      up to four dose cohorts of 8 subjects each. A single dose of study drug will be administered
      per cohort: 6 subjects will receive galidesivir IV, and 2 subjects will receive matching
      placebo.
    
  